Insights Into the Evolving Competitive Landscape of Global PARP Inhibitors Market | Key Companies – TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics

November 16 19:44 2022
Insights Into the Evolving Competitive Landscape of Global PARP Inhibitors Market | Key Companies - TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 30+ companies are working on 30+ drugs in the PARP Inhibitors pipeline landscape.

PARP Inhibitors Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  PARP Inhibitors Market. 

The PARP Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

PARP Inhibitor Pipeline Analysis

PARP Inhibitors Pipeline Analysis

  • The report provides detailed insights into emerging PARP Inhibitors in the pipeline and the aggregate therapies developed by major pharma companies.

  • It accesses the different PARP Inhibitors therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the PARP Inhibitors Market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 30+ products under different phases of clinical development like –

  • Late-stage products (Phase III and

  • Mid-stage products (Phase II and

  • Early-stage products (Phase I/II and Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

PARP Inhibitors Report – Key Strength

  • Active Pipeline Product Profiles

  • Inactive Drugs Review

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

  • Key Companies

Learn How the Ongoing Clinical & Commercial Activities will Affect the PARP Inhibitors Competitive Landscape in the Coming:

PARP Inhibitors Therapeutics Landscape

PARP is a family of proteins loosely based on structural similarity and function. PARP proteins comprise two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER.

There are approx. 30+ key companies developing PARP Inhibitors. Currently, BeiGene (Pamiparib) has its PARP Inhibitors drug candidates in the most advanced stage of clinical development.

Some of the key companies in the PARP Inhibitors Therapeutics Market include:


  • AstraZeneca

  • Sun BioPharma

  • Eisai Co

  • BeiGene

  • IMPACT Therapeutics

  • Ribon Therapeutics

And many others

PARP Inhibitors Products covered in the report include:

  • Niraparib  

  • Olaparib

  • SBP 101

  • 2X 121

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging PARP Inhibitors and Key Companies Actively Working in the Domain:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. PARP Inhibitors Current Treatment Patterns

4. PARP Inhibitors – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. PARP Inhibitors Late Stage Products (Phase-III)

7. PARP Inhibitors Mid-Stage Products (Phase-II)

8. PARP Inhibitors Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. PARP Inhibitors Discontinued Products

13. PARP Inhibitors Product Profiles

14. Key Companies in the PARP Inhibitors Market

15. Key Products in the PARP Inhibitors Therapeutics Segment

16. Dormant and Discontinued Products

17. PARP Inhibitors Unmet Needs

18. PARP Inhibitors Future Perspectives

19. PARP Inhibitors Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States